Nasopharyngeal angiofibroma: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(74 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{Infobox_Disease |
 
  Name          = {{PAGENAME}} |
__NOTOC__
  Image          = Nasopharyngeal angiofibroma 005.jpg|
  Caption        = |
  DiseasesDB    = 32229 |
  ICD10          = |
  ICD9          = |
  ICDO          = |
  OMIM          = |
  MedlinePlus    = 001572 |
  eMedicineSubj  = ent |
  eMedicineTopic = 470 |
  MeshID        = D018322 |
}}
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}; {{AE}}{{MA}}, {{MV}}


{{EH}}
{{SK}} Juvenile nasopharyngeal angiofibroma (JNA); [[angiofibroma]] of the [[nasopharynx]], nasopharyngeal fibroma, bleeding [[fibroma]] of adolescence, fibroangioma


==Overview==
==Overview==
Nasopharyngeal angiofibroma is a benign, vascular, polypoid [[fibrous]] mass in located in the the posterolateral wall of the [[nasal cavity]]. It was first described by Hippocrates, a Greek physician, in the 5th century BC. Nasopharyngeal angiofibroma may be classified according to Fisch classification into 4 groups. Nasopharyngeal angiofibroma is a histologically [[benign]] [[tumor]]. This tumor is located in the posterolateral wall of the [[nasal cavity]]. On gross pathology, characteristic findings of nasopharyngeal angiofibroma include tan to purple-red, rubbery-firm unencapsulated polypoid [[fibrous]] mass. [[Fibroblastic]] cells with plump (near cuboidal) [[nuclei]] and abundant [[capillaries]] are seen on microscopic histopathological analysis. The cause of Nasopharyngeal angiofibroma has not been identified, but it may be caused by [[hormonal]] effect. [[Incidence]] of juvenile nasopharyngeal angiofibroma is less than 0.5% of head and neck [[Tumor|tumors]]. If left untreated, %9 of patients with nasopharyngeal angiofibroma may progress to develop [[hemorrhage]] and intracranial extension. The hallmark of Nasopharyngeal angiofibroma is the classic triad of [[epistaxis]], unilateral nasal obstruction and a mass in the [[nasopharynx]]. Physical examination of patients with Nasopharyngeal angiofibroma is usually remarkable for nasal mass and [[rhinorrhea]]. Findings on an x-ray suggestive of nasopharyngeal angiofibroma include nasopharyngeal [[polyp]] and Antral sign or Holman-Miller sign (Forward bowing of the [[posterior]] wall of the [[maxillary sinus]]). CT scan and MRI demonstrate the extent of the tumor. The mainstay of treatment for nasopharyngeal angiofibroma is [[surgical resection]].
==Historical Perspective==
* Nasopharyngeal angiofibroma was first described by Hippocrates, a Greek physician, in the 5th century BC.<ref name="pmid22319699">{{cite journal |vauthors=Moorthy PN, Ranganatha Reddy B, Qaiyum HA, Madhira S, Kolloju S |title=Management of juvenile nasopharyngeal angiofibroma: a five year retrospective study |journal=Indian J Otolaryngol Head Neck Surg |volume=62 |issue=4 |pages=390–4 |date=October 2010 |pmid=22319699 |pmc=3266082 |doi=10.1007/s12070-010-0097-2 |url=}}</ref>
* In 1940, Friedberg was the first to use the term angiofibroma.
* The first [[endoscopic]] [[resection]] of nasopharyngeal angiofibroma was done in 1996. 
==Classification==
Nasopharyngeal angiofibroma may be classified according to '''Fisch classification''' into 4 groups: <ref name="pmid25991988">{{cite journal |vauthors=Martins MB, de Lima FV, Mendonça CA, de Jesus EP, Santos AC, Barreto VM, Santos RC |title=Nasopharyngeal angiofibroma: Our experience and literature review |journal=Int Arch Otorhinolaryngol |volume=17 |issue=1 |pages=14–9 |date=January 2013 |pmid=25991988 |pmc=4423317 |doi=10.7162/S1809-97772013000100003 |url=}}</ref>
* '''Type I''': [[Sphenopalatine foramen]], [[nasopharynx]], and nasal cavity are involved without [[bone]] destruction.
* '''Type II''': Nasal [[sinuses]] or the pterygomaxillary fossa are involved with [[bone]] destruction.
* '''Type IIIa''': [[Infratemporal fossa]] or [[orbit]] are involved without intracranial involvement.
* '''Type IIIb''': Infratemporal fossa or [[orbit]] are involved with intracranial extradural commitment.
* '''Type IVa''': Intracranial extradural and/or intradural are involved, but [[optic nerve]], [[sella]], or [[cavernous sinus]] are not involved.
* '''Type IVb''': Intracranial extradural and intradura, [[optic nerve]], [[sella]], and/or [[cavernous sinus]] are involved.
==Pathophysiology==
* Nasopharyngeal angiofibroma is a histologically [[benign]] [[tumor]].
* This tumor is located in the posterolateral wall of the [[nasal cavity]].
* Nasopharyngeal angiofibroma may involve [[sphenoid]] sinuses, [[maxillary]], [[ethmoid]], [[pterygoid plate]], [[orbit]], [[base of the skull]] and extradural.
* In rare cases, nasopharyngeal angiofibroma may involve [[pituitary]], [[cavernous sinus]] and/or [[optic chiasm]] and anterior [[fossa]]. <ref name="pmid15995507">{{cite journal |vauthors=Pryor SG, Moore EJ, Kasperbauer JL |title=Endoscopic versus traditional approaches for excision of juvenile nasopharyngeal angiofibroma |journal=Laryngoscope |volume=115 |issue=7 |pages=1201–7 |date=July 2005 |pmid=15995507 |doi=10.1097/01.MLG.0000162655.96247.66 |url=}}</ref>
*Genetic alterations associated with the development of nasopharyngeal angiofibroma include:<ref name="pmid18228521" />
:*Overexpression PDGF-B
:*Overexpression [[Basic fibroblast growth factor|BFGF]]
:*Deletion of chromosome 17
:*[[Tumor suppressor gene]] p53
:*Overexpression of Her-2/neu [[oncogene]]
*On gross pathology, characteristic findings of nasopharyngeal angiofibroma include:
**Bilobed or dumbbell-shaped with average size 3-5 cm  <ref name="pmid28632604">{{cite journal |vauthors=McKnight CD, Parmar HA, Watcharotone K, Mukherji SK |title=Reassessing the Anatomic Origin of the Juvenile Nasopharyngeal Angiofibroma |journal=J Comput Assist Tomogr |volume=41 |issue=4 |pages=559–564 |date=2017 |pmid=28632604 |doi=10.1097/RCT.0000000000000566 |url=}}</ref>
**Tan to purple-red, rubbery-firm unencapsulated polypoid [[fibrous]] mass
**Bleeding on [[biopsy]]
**Spongy cut surface
**[[Sessile]] or [[pedunculated]] [[tumor]]
*On microscopic histopathological analysis, characteristic findings of nasopharyngeal angiofibroma include:
:*[[Fibroblastic]] cells with plump (near cuboidal) [[nuclei]]
:*Fibrous [[stroma]]
:*Abundant [[capillaries]]
:*[[Multinucleated]] [[stromal cells]]
==Causes==
* The cause of Nasopharyngeal angiofibroma has not been identified, but it may be caused by [[hormonal]] effect.<ref name="pmid25384380">{{cite journal |vauthors=Liu Z, Wang J, Wang H, Wang D, Hu L, Liu Q, Sun X |title=Hormonal receptors and vascular endothelial growth factor in juvenile nasopharyngeal angiofibroma: immunohistochemical and tissue microarray analysis |journal=Acta Otolaryngol. |volume=135 |issue=1 |pages=51–7 |date=January 2015 |pmid=25384380 |doi=10.3109/00016489.2014.952774 |url=}}</ref>
* Nasopharyngeal angiofibroma express higher levels of [[vascular endothelial growth factor]] (VEGF) and [[hormone]] [[receptors]].
==Differentiating Nasopharyngeal angiofibroma from Other Diseases==
Nasopharyngeal angiofibroma must be differentiated from other diseases that cause [[epistaxis]], unilateral [[nasal]] obstruction, and [[rhinorrhea]], such as:<ref name="pmid30038985">{{cite journal |vauthors=Alimli AG, Ucar M, Oztunali C, Akkan K, Boyunaga O, Damar C, Derinkuyu B, Tokgöz N |title=Juvenile Nasopharyngeal Angiofibroma: Magnetic Resonance Imaging Findings |journal=J Belg Soc Radiol |volume=100 |issue=1 |pages=63 |date=June 2016 |pmid=30038985 |pmc=5854277 |doi=10.5334/jbr-btr.1090 |url=}}</ref>
:* Sinonasal [[polyp]]
:* [[Rhinosporidiosis]]
:* [[Chordoma]]
:* [[Nasopharyngeal]] [[cyst]]
:* [[Pyogenic granuloma]]
:* [[Nasopharyngeal carcinoma]]
:* [[Lymphoma]]
:* [[Rhabdomyosarcoma]]
:* [[Adenoid]] [[hypertrophy]]
==Epidemiology and Demographics==
* [[Incidence]] of juvenile nasopharyngeal angiofibroma is less than 0.5% of head and neck [[Tumor|tumors]]. <ref name="pmid13230032">{{cite journal |vauthors=Gullane PJ, Davidson J, O'Dwyer T, Forte V |title=Juvenile angiofibroma: a review of the literature and a case series report |journal=Laryngoscope |volume=102 |issue=8 |pages=928–33 |date=August 1992 |pmid=1323003 |doi=10.1288/00005537-199208000-00014 |url=}}</ref>
* The [[incidence]] of juvenile nasopharyngeal angiofibroma is 0.6 per 100,000 individuals worldwide.<ref name="pmid182285212">{{cite journal |vauthors=Coutinho-Camillo CM, Brentani MM, Nagai MA |title=Genetic alterations in juvenile nasopharyngeal angiofibromas |journal=Head Neck |volume=30 |issue=3 |pages=390–400 |date=March 2008 |pmid=18228521 |doi=10.1002/hed.20775 |url=}}</ref>
* Some reports suggest juvenile nasopharyngeal angiofibroma is more common in the Indian subcontinent than in the west.<ref name="pmid17368816">{{cite journal |vauthors=Biswas D, Saha S, Bera SP |title=Relative distribution of the tumours of ear, nose and throat in the paediatric patients |journal=Int. J. Pediatr. Otorhinolaryngol. |volume=71 |issue=5 |pages=801–5 |date=May 2007 |pmid=17368816 |doi=10.1016/j.ijporl.2007.01.021 |url=}}</ref>
* Men are more commonly affected by juvenile nasopharyngeal angiofibroma than women.
==Risk Factors==
Common [[risk factors]] in the development of nasopharyngeal angiofibroma include:<ref name="pmid18227724">{{cite journal |vauthors=Ponti G, Losi L, Pellacani G, Rossi GB, Presutti L, Mattioli F, Villari D, Wannesson L, Alicandri Ciufelli M, Izzo P, De Rosa M, Marone P, Seidenari S |title=Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA) |journal=Appl. Immunohistochem. Mol. Morphol. |volume=16 |issue=2 |pages=173–8 |date=March 2008 |pmid=18227724 |doi=10.1097/PAI.0b013e31806bee12 |url=}}</ref>
* [[Familial adenomatous polyposis]]
* Male gender
*
==Screening==
* There is insufficient evidence to recommend routine [[screening]] for nasopharyngeal angiofibroma.


'''Nasopharyngeal angiofibroma''' (also called juvenile nasopharyngeal angiofibroma) is a histologically [[benign]] but locally aggressive vascular tumor that grows in the back of the nasal cavity. It almost exclusively affects adolescent males. Patients with nasopharyngeal angiofibroma usually present with one-sided nasal obstruction and recurrent bleeding.
==Natural History, Complications, and Prognosis==
* If left untreated, %9 of patients with nasopharyngeal angiofibroma may progress to develop [[hemorrhage]] and intracranial extension.


==Differential Diagnosis==
* Common complications of nasopharengeal angiofibroma include nasal [[obstruction]] and repeated [[bleeding]].<ref name="pmid28286392">{{cite journal |vauthors=Roy Chowdhury S, Rajkumar K, Deshmukh T |title=Complications of Midface Swing for Management of Juvenile Nasopharyngeal Angiofibroma |journal=J Maxillofac Oral Surg |volume=16 |issue=1 |pages=96–100 |date=March 2017 |pmid=28286392 |pmc=5328877 |doi=10.1007/s12663-016-0947-x |url=}}</ref>


* Antro-choanal polyp (antral-choanal polyp)
* In general prognosis of nasopharyngeal angiofibroma is good.
* Rhinosporidiosis
* Malignancy
* Chordoma
* Nasopharanageal cyst
* Pyogenic granuloma


==Diagnosis==
==Diagnosis==
===Diagnostic Study of Choice===
The diagnosis of nasopharyngeal angiofibroma is made when the following findings are met:
* [[Epistaxis]]
* Unilateral nasal [[obstruction]]
* Mass in the [[nasopharynx]]
===History and Symptoms===
* The hallmark of Nasopharyngeal angiofibroma is the classic triad of [[epistaxis]], unilateral nasal obstruction and a mass in the [[nasopharynx]].
* The most common symptoms of Nasopharyngeal angiofibroma include nasal obstruction, [[epistaxis]] and [[headache]].
* Less common symptoms of Nasopharyngeal angiofibroma include [[conductive hearing loss]], [[diplopia]], [[proptosis]], [[anosmia]], recurrent [[otitis media]] and eye pain. <ref name="pmid15548906" />


===Symptoms===
===Physical Examination===
* Physical examination of patients with Nasopharyngeal angiofibroma is usually remarkable for '''nasal mass and [[rhinorrhea]]'''.<ref name="pmid15548906">{{cite journal |vauthors=Enepekides DJ |title=Recent advances in the treatment of juvenile angiofibroma |journal=Curr Opin Otolaryngol Head Neck Surg |volume=12 |issue=6 |pages=495–9 |date=December 2004 |pmid=15548906 |doi= |url=}}</ref>
* Rare physical examination include:


* Frequent epistaxis or blood-tinged nasal discharge
** [[Orbit (anatomy)|Orbital]] mass
* Nasal obstruction and rhinorrhea
** [[Proptosis]]
* Conductive hearing loss from eustachian-tube obstruction
** [[Zygomatic]] [[swelling]]
* Diplopia, which occurs secondary to erosion into the cranial cavity and pressure on the optic chiasma
** [[Trismus]]
* Rarely anosmia, recurrent otitis media, and eye pain
** Decreasing [[vision]]
*  
*  


===CT and MRI===
===Laboratory Findings===


If nasopharyngeal angiofibroma is suspected based on physical exam (a smooth submucosal mass in the posterior nasal cavity), imaging studies such as [[Computed_tomography|CT]] or [[Magnetic resonance imaging|MRI]] should be performed.
There are no diagnostic laboratory findings associated with nasopharyngeal angiofibroma.  


[http://www.peir.net Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
===Electrocardiogram===
There are no ECG findings associated with nasopharyngeal angiofibroma.  


[[Image:Nasopharyngeal angiofibroma 001.jpg|left|350px|thumb|CT: Nasopharyngeal angiofibroma. Skull base invasion]]
===X-ray===
<br clear="left"/>
An x-ray may be helpful in the diagnosis of nasopharyngeal angiofibroma. Findings on an x-ray suggestive of nasopharyngeal angiofibroma include:<ref name="pmid26046027">{{cite journal |vauthors=Ikubor JE, Okolugbo NE, Okhakhu AL |title=Radiological features of juvenile nasopharyngeal angiofibroma |journal=J West Afr Coll Surg |volume=3 |issue=4 |pages=84–91 |date=2013 |pmid=26046027 |pmc=4437236 |doi= |url=}}</ref>
* Nasopharyngeal [[polyp]]
* Antral sign or Holman-Miller sign: Forward bowing of the [[posterior]] wall of the [[maxillary sinus]]
* [[Maxillary sinus]] opacification
* Bony margin may be eroded


[[Image:Nasopharyngeal angiofibroma 002.jpg|left|350px|thumb|MRI (T1): Nasopharyngeal angiofibroma. 1/3 ]]
===Echocardiography or Ultrasound===
<br clear="left"/>
* There are no echocardiography/ultrasound findings associated with nasopharyngeal angiofibroma.  


[[Image:Nasopharyngeal angiofibroma 003.jpg|left|350px|thumb|MRI (T1): Nasopharyngeal angiofibroma. 2/3 ]]
===CT scan===
<br clear="left"/>
CT scan demonstrate the extent of the tumor. Findings on CT scan suggestive of nasopharengeal angiofibroma include:<ref name="pmid23878770">{{cite journal |vauthors=Mishra S, Praveena NM, Panigrahi RG, Gupta YM |title=Imaging in the diagnosis of juvenile nasopharyngeal angiofibroma |journal=J Clin Imaging Sci |volume=3 |issue=Suppl 1 |pages=1 |date=2013 |pmid=23878770 |pmc=3716018 |doi=10.4103/2156-7514.109469 |url=}}</ref>
* Extension to the [[sphenoid sinus]]
* Erosion of the greater sphenoidal wing
* invasion of the [[pterygomaxillary]] and infratemporal fossae


[[Image:Nasopharyngeal angiofibroma 004.jpg|left|350px|thumb|MRI (T1): Nasopharyngeal angiofibroma. 3/3 ]]
===MRI===
<br clear="left"/>
Cronal MRI demonstrate the extent of the tumor especially in intracranial involvement. <ref name="pmid238787702">{{cite journal |vauthors=Mishra S, Praveena NM, Panigrahi RG, Gupta YM |title=Imaging in the diagnosis of juvenile nasopharyngeal angiofibroma |journal=J Clin Imaging Sci |volume=3 |issue=Suppl 1 |pages=1 |date=2013 |pmid=23878770 |pmc=3716018 |doi=10.4103/2156-7514.109469 |url=}}</ref>
* Findings on MRI suggestive of nasopharengeal angiofibroma include:<ref name="pmid300389852">{{cite journal |vauthors=Alimli AG, Ucar M, Oztunali C, Akkan K, Boyunaga O, Damar C, Derinkuyu B, Tokgöz N |title=Juvenile Nasopharyngeal Angiofibroma: Magnetic Resonance Imaging Findings |journal=J Belg Soc Radiol |volume=100 |issue=1 |pages=63 |date=June 2016 |pmid=30038985 |pmc=5854277 |doi=10.5334/jbr-btr.1090 |url=}}</ref>
** Largely isointense to muscle on T1-weighted images
** Hyperintense on T2-weighted images
** Internal signal-void regions
** Intense enhancement after [[intravenous]] (IV) [[contrast]] injection
The images below demonstrate findings of nasopharyngeal angiofibroma.
<gallery>
Image:Nasopharyngeal angiofibroma 001.jpg| Nasopharyngeal angiofibroma. Skull base invasion[http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
Image:Nasopharyngeal angiofibroma 002.jpg|MRI (T1): Nasopharyngeal angiofibroma 1/3 [http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
Image:Nasopharyngeal angiofibroma 003.jpg| MRI (T1): Nasopharyngeal angiofibroma [http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
Image:Nasopharyngeal angiofibroma 004.jpg| MRI (T1): Nasopharyngeal angiofibroma 3/3 [http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
Image:Nasopharyngeal angiofibroma 005.jpg| MRI (T1): Nasopharyngeal angiofibroma 3/3 (circled)[http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
</gallery>


[[Image:Nasopharyngeal angiofibroma 005.jpg|left|350px|thumb|MRI (T1): Nasopharyngeal angiofibroma. 3/3 (circled)]]
<br clear="left"/>


===Biopsy===


Biopsy can lead to extensive bleeding since the tumor is composed of blood vessels without a muscular coat.
===Other Imaging Findings===


==Treatment==
[[Digital subtraction angiography|DSA]] ([[digital subtraction angiography]]) of [[carotid artery]] is helpful in the diagnosis extension of nasopharengeal angiofibroma and feeding [[vessel]].<ref name="pmid16775738">{{cite journal |vauthors=Giavroglou C, Constantinidis J, Triaridis S, Daniilidis J, Dimitriadis A |title=[Angiographic evaluation and embolization of juvenile nasopharyngeal angiofibroma] |language=German |journal=HNO |volume=55 |issue=1 |pages=36–41 |date=January 2007 |pmid=16775738 |doi=10.1007/s00106-006-1410-y |url=}}</ref>


Nasopharyngeal angiofibroma is treated by surgery. Medical treatment is usually given before surgery to reduce the blood loss - includes the usage of Diethylstilbestrol 2-3 weeks before surgery to make the surgery relatively less vascular.
===Other Diagnostic Studies===
Other diagnostic studies for nasopharengeal angiofibroma include nasal endoscopy, which demonstrates hypervascularized large, lobulated mass behind the middle turbinate.<ref name="pmid27601836">{{cite journal |vauthors=Makhasana JA, Kulkarni MA, Vaze S, Shroff AS |title=Juvenile nasopharyngeal angiofibroma |journal=J Oral Maxillofac Pathol |volume=20 |issue=2 |pages=330 |date=2016 |pmid=27601836 |pmc=4989574 |doi=10.4103/0973-029X.185908 |url=}}</ref><ref name="pmid221641852">{{cite journal |vauthors=Nicolai P, Schreiber A, Bolzoni Villaret A |title=Juvenile angiofibroma: evolution of management |journal=Int J Pediatr |volume=2012 |issue= |pages=412545 |date=2012 |pmid=22164185 |doi=10.1155/2012/412545 |url=}}</ref>


Pre-surgery [[angiography]] may allow for [[embolization]], reducing intraoperative blood loss. Hypotensive anaesthesia is the usual modality followed to reduce blood loss. Patients with tumors that have extended into the cranial cavity or whose tumors can't be safely reached by surgery may receive [[radiation therapy]]. Also radiation therapy helps in case where recurrence is the main problem.
=== Medical Therapy ===
The mainstay of treatment for nasopharyngeal angiofibroma is [[surgical resection]].
* Medical therapies for nasopharyngeal angiofibroma include: <ref name="pmid155489062">{{cite journal |vauthors=Enepekides DJ |title=Recent advances in the treatment of juvenile angiofibroma |journal=Curr Opin Otolaryngol Head Neck Surg |volume=12 |issue=6 |pages=495–9 |date=December 2004 |pmid=15548906 |doi= |url=}}</ref>
** [[Hormones]] ([[estrogen]], [[testosterone]])
** [[Radiation therapy]]
** [[Chemotherapy]]
** [[Embolization]]


[[Endoscopy]] has recently been used in patients with tumors of limited extension that have been pre-operatively embolized. Then, lateral rhinotomy is the usual preferred technique these days, an incision along the lateral border of nose is required to explore the maxillary antrum and remove the pathology. Other useful method is degloving technique which requires adequate operator skills.
===Surgery===
[[Arteriography]] followed by preoperative [[embolization]] and [[surgical resection]] is the mainstay of treatment for nasopharyngeal angiofibroma. <ref name="pmid221641854">{{cite journal |vauthors=Nicolai P, Schreiber A, Bolzoni Villaret A |title=Juvenile angiofibroma: evolution of management |journal=Int J Pediatr |volume=2012 |issue= |pages=412545 |date=2012 |pmid=22164185 |pmc=3228400 |doi=10.1155/2012/412545 |url=}}</ref>
* Surgical approaches for nasopharyngeal angiofibroma include: <ref name="pmid221641853">{{cite journal |vauthors=Nicolai P, Schreiber A, Bolzoni Villaret A |title=Juvenile angiofibroma: evolution of management |journal=Int J Pediatr |volume=2012 |issue= |pages=412545 |date=2012 |pmid=22164185 |doi=10.1155/2012/412545 |url=}}</ref>
** Transpalatal
** Transmaxillary
** Lateral rhinotomy
** Mid-facial degloving
** Extended sublabial Denker
** Le Fort type I [[osteotomy]]
** [[Endoscopic surgery]]
 
===Primary Prevention===
There are no established measures for the primary prevention of Nasopharyngeal angiofibroma.
 
===Secondary Prevention===
Once diagnosed and successfully treated, patients with nasopharyngeal angiofibroma are followed-up after surgery, and every 6 or 12 months, depending on the clinical progression.


==References==
==References==
{{reflist|2}}


* Richard R. Orlandi. Nose and sinuses from Oxford Textbook of Surgery - 2nd Ed. Peter J. Morris and William C. Wood editors, Oxford University Press, Oxford, UK, 2000.
{{WikiDoc Help Menu}}
* {{cite journal |author=Douglas R, Wormald P |title=Endoscopic surgery for juvenile nasopharyngeal angiofibroma: where are the limits? |journal=Curr Opin Otolaryngol Head Neck Surg |volume=14 |issue=1 |pages=1-5 |year=2006 |pmid=16467630}}
{{WikiDoc Sources}}




{{Tumors of lip, oral cavity and pharynx}}
{{WH}}
{{SIB}}
{{WS}}
[[Category:Diseases]]
 
[[Category:Disease]]
[[Category:Otolaryngology]]
[[Category:Otolaryngology]]
[[Category:Oncology]]
[[Category:Oncology]]
 
[[Category:Up-To-Date]]
{{WH}}
[[Category:Oncology]]
{{WS}}
[[Category:Medicine]]
[[Category:Otolaryngology]]

Latest revision as of 15:00, 27 February 2019


WikiDoc Resources for Nasopharyngeal angiofibroma

Articles

Most recent articles on Nasopharyngeal angiofibroma

Most cited articles on Nasopharyngeal angiofibroma

Review articles on Nasopharyngeal angiofibroma

Articles on Nasopharyngeal angiofibroma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nasopharyngeal angiofibroma

Images of Nasopharyngeal angiofibroma

Photos of Nasopharyngeal angiofibroma

Podcasts & MP3s on Nasopharyngeal angiofibroma

Videos on Nasopharyngeal angiofibroma

Evidence Based Medicine

Cochrane Collaboration on Nasopharyngeal angiofibroma

Bandolier on Nasopharyngeal angiofibroma

TRIP on Nasopharyngeal angiofibroma

Clinical Trials

Ongoing Trials on Nasopharyngeal angiofibroma at Clinical Trials.gov

Trial results on Nasopharyngeal angiofibroma

Clinical Trials on Nasopharyngeal angiofibroma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nasopharyngeal angiofibroma

NICE Guidance on Nasopharyngeal angiofibroma

NHS PRODIGY Guidance

FDA on Nasopharyngeal angiofibroma

CDC on Nasopharyngeal angiofibroma

Books

Books on Nasopharyngeal angiofibroma

News

Nasopharyngeal angiofibroma in the news

Be alerted to news on Nasopharyngeal angiofibroma

News trends on Nasopharyngeal angiofibroma

Commentary

Blogs on Nasopharyngeal angiofibroma

Definitions

Definitions of Nasopharyngeal angiofibroma

Patient Resources / Community

Patient resources on Nasopharyngeal angiofibroma

Discussion groups on Nasopharyngeal angiofibroma

Patient Handouts on Nasopharyngeal angiofibroma

Directions to Hospitals Treating Nasopharyngeal angiofibroma

Risk calculators and risk factors for Nasopharyngeal angiofibroma

Healthcare Provider Resources

Symptoms of Nasopharyngeal angiofibroma

Causes & Risk Factors for Nasopharyngeal angiofibroma

Diagnostic studies for Nasopharyngeal angiofibroma

Treatment of Nasopharyngeal angiofibroma

Continuing Medical Education (CME)

CME Programs on Nasopharyngeal angiofibroma

International

Nasopharyngeal angiofibroma en Espanol

Nasopharyngeal angiofibroma en Francais

Business

Nasopharyngeal angiofibroma in the Marketplace

Patents on Nasopharyngeal angiofibroma

Experimental / Informatics

List of terms related to Nasopharyngeal angiofibroma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2], Maria Fernanda Villarreal, M.D. [3]

Synonyms and keywords: Juvenile nasopharyngeal angiofibroma (JNA); angiofibroma of the nasopharynx, nasopharyngeal fibroma, bleeding fibroma of adolescence, fibroangioma

Overview

Nasopharyngeal angiofibroma is a benign, vascular, polypoid fibrous mass in located in the the posterolateral wall of the nasal cavity. It was first described by Hippocrates, a Greek physician, in the 5th century BC. Nasopharyngeal angiofibroma may be classified according to Fisch classification into 4 groups. Nasopharyngeal angiofibroma is a histologically benign tumor. This tumor is located in the posterolateral wall of the nasal cavity. On gross pathology, characteristic findings of nasopharyngeal angiofibroma include tan to purple-red, rubbery-firm unencapsulated polypoid fibrous mass. Fibroblastic cells with plump (near cuboidal) nuclei and abundant capillaries are seen on microscopic histopathological analysis. The cause of Nasopharyngeal angiofibroma has not been identified, but it may be caused by hormonal effect. Incidence of juvenile nasopharyngeal angiofibroma is less than 0.5% of head and neck tumors. If left untreated, %9 of patients with nasopharyngeal angiofibroma may progress to develop hemorrhage and intracranial extension. The hallmark of Nasopharyngeal angiofibroma is the classic triad of epistaxis, unilateral nasal obstruction and a mass in the nasopharynx. Physical examination of patients with Nasopharyngeal angiofibroma is usually remarkable for nasal mass and rhinorrhea. Findings on an x-ray suggestive of nasopharyngeal angiofibroma include nasopharyngeal polyp and Antral sign or Holman-Miller sign (Forward bowing of the posterior wall of the maxillary sinus). CT scan and MRI demonstrate the extent of the tumor. The mainstay of treatment for nasopharyngeal angiofibroma is surgical resection.

Historical Perspective

  • Nasopharyngeal angiofibroma was first described by Hippocrates, a Greek physician, in the 5th century BC.[1]
  • In 1940, Friedberg was the first to use the term angiofibroma.
  • The first endoscopic resection of nasopharyngeal angiofibroma was done in 1996.

Classification

Nasopharyngeal angiofibroma may be classified according to Fisch classification into 4 groups: [2]

Pathophysiology

  • Nasopharyngeal angiofibroma is a histologically benign tumor.
  • Genetic alterations associated with the development of nasopharyngeal angiofibroma include:[4]
  • On gross pathology, characteristic findings of nasopharyngeal angiofibroma include:
  • On microscopic histopathological analysis, characteristic findings of nasopharyngeal angiofibroma include:

Causes

  • The cause of Nasopharyngeal angiofibroma has not been identified, but it may be caused by hormonal effect.[6]

Differentiating Nasopharyngeal angiofibroma from Other Diseases

Nasopharyngeal angiofibroma must be differentiated from other diseases that cause epistaxis, unilateral nasal obstruction, and rhinorrhea, such as:[7]

Epidemiology and Demographics

  • Incidence of juvenile nasopharyngeal angiofibroma is less than 0.5% of head and neck tumors. [8]
  • The incidence of juvenile nasopharyngeal angiofibroma is 0.6 per 100,000 individuals worldwide.[9]
  • Some reports suggest juvenile nasopharyngeal angiofibroma is more common in the Indian subcontinent than in the west.[10]
  • Men are more commonly affected by juvenile nasopharyngeal angiofibroma than women.

Risk Factors

Common risk factors in the development of nasopharyngeal angiofibroma include:[11]

Screening

  • There is insufficient evidence to recommend routine screening for nasopharyngeal angiofibroma.

Natural History, Complications, and Prognosis

  • If left untreated, %9 of patients with nasopharyngeal angiofibroma may progress to develop hemorrhage and intracranial extension.
  • In general prognosis of nasopharyngeal angiofibroma is good.

Diagnosis

Diagnostic Study of Choice

The diagnosis of nasopharyngeal angiofibroma is made when the following findings are met:

History and Symptoms

Physical Examination

  • Physical examination of patients with Nasopharyngeal angiofibroma is usually remarkable for nasal mass and rhinorrhea.[13]
  • Rare physical examination include:

Laboratory Findings

There are no diagnostic laboratory findings associated with nasopharyngeal angiofibroma.

Electrocardiogram

There are no ECG findings associated with nasopharyngeal angiofibroma.

X-ray

An x-ray may be helpful in the diagnosis of nasopharyngeal angiofibroma. Findings on an x-ray suggestive of nasopharyngeal angiofibroma include:[14]

Echocardiography or Ultrasound

  • There are no echocardiography/ultrasound findings associated with nasopharyngeal angiofibroma.

CT scan

CT scan demonstrate the extent of the tumor. Findings on CT scan suggestive of nasopharengeal angiofibroma include:[15]

MRI

Cronal MRI demonstrate the extent of the tumor especially in intracranial involvement. [16]

  • Findings on MRI suggestive of nasopharengeal angiofibroma include:[17]
    • Largely isointense to muscle on T1-weighted images
    • Hyperintense on T2-weighted images
    • Internal signal-void regions
    • Intense enhancement after intravenous (IV) contrast injection

The images below demonstrate findings of nasopharyngeal angiofibroma.


Other Imaging Findings

DSA (digital subtraction angiography) of carotid artery is helpful in the diagnosis extension of nasopharengeal angiofibroma and feeding vessel.[18]

Other Diagnostic Studies

Other diagnostic studies for nasopharengeal angiofibroma include nasal endoscopy, which demonstrates hypervascularized large, lobulated mass behind the middle turbinate.[19][20]

Medical Therapy

The mainstay of treatment for nasopharyngeal angiofibroma is surgical resection.

Surgery

Arteriography followed by preoperative embolization and surgical resection is the mainstay of treatment for nasopharyngeal angiofibroma. [22]

  • Surgical approaches for nasopharyngeal angiofibroma include: [23]
    • Transpalatal
    • Transmaxillary
    • Lateral rhinotomy
    • Mid-facial degloving
    • Extended sublabial Denker
    • Le Fort type I osteotomy
    • Endoscopic surgery

Primary Prevention

There are no established measures for the primary prevention of Nasopharyngeal angiofibroma.

Secondary Prevention

Once diagnosed and successfully treated, patients with nasopharyngeal angiofibroma are followed-up after surgery, and every 6 or 12 months, depending on the clinical progression.

References

  1. ↑ Moorthy PN, Ranganatha Reddy B, Qaiyum HA, Madhira S, Kolloju S (October 2010). "Management of juvenile nasopharyngeal angiofibroma: a five year retrospective study". Indian J Otolaryngol Head Neck Surg. 62 (4): 390–4. doi:10.1007/s12070-010-0097-2. PMC 3266082. PMID 22319699.
  2. ↑ Martins MB, de Lima FV, Mendonça CA, de Jesus EP, Santos AC, Barreto VM, Santos RC (January 2013). "Nasopharyngeal angiofibroma: Our experience and literature review". Int Arch Otorhinolaryngol. 17 (1): 14–9. doi:10.7162/S1809-97772013000100003. PMC 4423317. PMID 25991988.
  3. ↑ Pryor SG, Moore EJ, Kasperbauer JL (July 2005). "Endoscopic versus traditional approaches for excision of juvenile nasopharyngeal angiofibroma". Laryngoscope. 115 (7): 1201–7. doi:10.1097/01.MLG.0000162655.96247.66. PMID 15995507.
  4. ↑
  5. ↑ McKnight CD, Parmar HA, Watcharotone K, Mukherji SK (2017). "Reassessing the Anatomic Origin of the Juvenile Nasopharyngeal Angiofibroma". J Comput Assist Tomogr. 41 (4): 559–564. doi:10.1097/RCT.0000000000000566. PMID 28632604.
  6. ↑ Liu Z, Wang J, Wang H, Wang D, Hu L, Liu Q, Sun X (January 2015). "Hormonal receptors and vascular endothelial growth factor in juvenile nasopharyngeal angiofibroma: immunohistochemical and tissue microarray analysis". Acta Otolaryngol. 135 (1): 51–7. doi:10.3109/00016489.2014.952774. PMID 25384380.
  7. ↑ Alimli AG, Ucar M, Oztunali C, Akkan K, Boyunaga O, Damar C, Derinkuyu B, Tokgöz N (June 2016). "Juvenile Nasopharyngeal Angiofibroma: Magnetic Resonance Imaging Findings". J Belg Soc Radiol. 100 (1): 63. doi:10.5334/jbr-btr.1090. PMC 5854277. PMID 30038985.
  8. ↑ Gullane PJ, Davidson J, O'Dwyer T, Forte V (August 1992). "Juvenile angiofibroma: a review of the literature and a case series report". Laryngoscope. 102 (8): 928–33. doi:10.1288/00005537-199208000-00014. PMID 1323003.
  9. ↑ Coutinho-Camillo CM, Brentani MM, Nagai MA (March 2008). "Genetic alterations in juvenile nasopharyngeal angiofibromas". Head Neck. 30 (3): 390–400. doi:10.1002/hed.20775. PMID 18228521.
  10. ↑ Biswas D, Saha S, Bera SP (May 2007). "Relative distribution of the tumours of ear, nose and throat in the paediatric patients". Int. J. Pediatr. Otorhinolaryngol. 71 (5): 801–5. doi:10.1016/j.ijporl.2007.01.021. PMID 17368816.
  11. ↑ Ponti G, Losi L, Pellacani G, Rossi GB, Presutti L, Mattioli F, Villari D, Wannesson L, Alicandri Ciufelli M, Izzo P, De Rosa M, Marone P, Seidenari S (March 2008). "Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA)". Appl. Immunohistochem. Mol. Morphol. 16 (2): 173–8. doi:10.1097/PAI.0b013e31806bee12. PMID 18227724.
  12. ↑ Roy Chowdhury S, Rajkumar K, Deshmukh T (March 2017). "Complications of Midface Swing for Management of Juvenile Nasopharyngeal Angiofibroma". J Maxillofac Oral Surg. 16 (1): 96–100. doi:10.1007/s12663-016-0947-x. PMC 5328877. PMID 28286392.
  13. ↑ 13.0 13.1 Enepekides DJ (December 2004). "Recent advances in the treatment of juvenile angiofibroma". Curr Opin Otolaryngol Head Neck Surg. 12 (6): 495–9. PMID 15548906.
  14. ↑ Ikubor JE, Okolugbo NE, Okhakhu AL (2013). "Radiological features of juvenile nasopharyngeal angiofibroma". J West Afr Coll Surg. 3 (4): 84–91. PMC 4437236. PMID 26046027.
  15. ↑ Mishra S, Praveena NM, Panigrahi RG, Gupta YM (2013). "Imaging in the diagnosis of juvenile nasopharyngeal angiofibroma". J Clin Imaging Sci. 3 (Suppl 1): 1. doi:10.4103/2156-7514.109469. PMC 3716018. PMID 23878770.
  16. ↑ Mishra S, Praveena NM, Panigrahi RG, Gupta YM (2013). "Imaging in the diagnosis of juvenile nasopharyngeal angiofibroma". J Clin Imaging Sci. 3 (Suppl 1): 1. doi:10.4103/2156-7514.109469. PMC 3716018. PMID 23878770.
  17. ↑ Alimli AG, Ucar M, Oztunali C, Akkan K, Boyunaga O, Damar C, Derinkuyu B, Tokgöz N (June 2016). "Juvenile Nasopharyngeal Angiofibroma: Magnetic Resonance Imaging Findings". J Belg Soc Radiol. 100 (1): 63. doi:10.5334/jbr-btr.1090. PMC 5854277. PMID 30038985.
  18. ↑ Giavroglou C, Constantinidis J, Triaridis S, Daniilidis J, Dimitriadis A (January 2007). "[Angiographic evaluation and embolization of juvenile nasopharyngeal angiofibroma]". HNO (in German). 55 (1): 36–41. doi:10.1007/s00106-006-1410-y. PMID 16775738.
  19. ↑ Makhasana JA, Kulkarni MA, Vaze S, Shroff AS (2016). "Juvenile nasopharyngeal angiofibroma". J Oral Maxillofac Pathol. 20 (2): 330. doi:10.4103/0973-029X.185908. PMC 4989574. PMID 27601836.
  20. ↑ Nicolai P, Schreiber A, Bolzoni Villaret A (2012). "Juvenile angiofibroma: evolution of management". Int J Pediatr. 2012: 412545. doi:10.1155/2012/412545. PMID 22164185.
  21. ↑ Enepekides DJ (December 2004). "Recent advances in the treatment of juvenile angiofibroma". Curr Opin Otolaryngol Head Neck Surg. 12 (6): 495–9. PMID 15548906.
  22. ↑ Nicolai P, Schreiber A, Bolzoni Villaret A (2012). "Juvenile angiofibroma: evolution of management". Int J Pediatr. 2012: 412545. doi:10.1155/2012/412545. PMC 3228400. PMID 22164185.
  23. ↑ Nicolai P, Schreiber A, Bolzoni Villaret A (2012). "Juvenile angiofibroma: evolution of management". Int J Pediatr. 2012: 412545. doi:10.1155/2012/412545. PMID 22164185.


Template:WikiDoc Sources


Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Nasopharyngeal_angiofibroma&oldid=1554584"